 
<prompt> Trends in IPTp | Percentage of women with a live birth in the 2 years before the survey who received at least 1, 2, or 3 doses of SP/Fansidar | (IPTp3+, 2009 UMIS, 17) (IPTp2+, 2009 UMIS, 33) (IPTp1+, 2009 UMIS, 47) (IPTp3+, 2011 UDHS, 10) (IPTp2+, 2011 UDHS, 27) (IPTp1+, 2011 UDHS, 48) (IPTp3+, 2014-15 UMIS, 28) (IPTp2+, 2014-15 UMIS, 49) (IPTp1+, 2014-15 UMIS, 64) (IPTp3+, 2016 UDHS, 17) (IPTp2+, 2016 UDHS, 46) (IPTp1+, 2016 UDHS, 79) (IPTp3+, 2018-19 UMIS, 41) (IPTp2+, 2018-19 UMIS, 72) (IPTp1+, 2018-19 UMIS, 89) <response> The percentage of women receiving IPTp1+ increased from 47% in the 2009 UMIS to 89% in the 2018-19 UMIS. The percentage of women receiving two or more doses of SP/Fansidar for IPTp increased from 33% in the 2009 UMIS to 72% in the 2018-19 UMIS. Similarly, the percentage of women receiving three or more doses of SP/Fansidar for IPTp increased from 17% in the 2009 UMIS to 41% in the 2018-19 UMIS  